Key Highlights
● DocGo shares have ticked modestly higher over the past month, moving off record lows even as the stock remains under pressure.
● The company faces an active Nasdaq compliance clock heading into its second-quarter Earnings report.
● DocGo is a mobile health and medical transportation company best known for ambulance services and its now-defunct New York City migrant-services contract.
● The convergence of the compliance deadline and upcoming earnings makes the coming weeks pivotal for DocGo's trajectory.
DocGo Inc. (NASDAQ: DCGO), the mobile health and medical transportation company best known for ambulance services and, more controversially, for its now-defunct New York City migrant-services contract, has seen its stock tick modestly higher over the past month even as it trades under $1 and faces a Nasdaq listing-compliance deadline. Shares closed around $0.65–$0.67 in mid-August, up roughly 3.5% over the trailing month and about 13% over three months, according to Barchart data, but still down more than half over the past year. The move comes just ahead of DocGo's second-quarter 2026 earnings release, scheduled for after markets close on Monday, August 17, one day after this article's reporting date, following a delayed 10-Q filing.
Latest Development
The most immediate news is procedural but notable: on August 10, 2026, DocGo filed a Form NT 10-Q with the SEC, formally notifying regulators it needed additional time to complete its second-quarter financial statements and would use the five-business-day extension permitted under SEC Rule 12b-25. The filing stated the company did not anticipate a significant change in operating results compared with the prior-year period and that all other periodic filings over the past 12 months had been timely. DocGo has said it will report Q2 2026 results (for the quarter ended June 30, 2026) after the market close on August 17, with a conference call at 5:00 p.m. ET. As of this writing, no single company-specific announcement could be independently verified as explaining the stock's recent uptick; it appears to reflect general positioning ahead of that earnings release combined with a stock trading near multi-year lows, rather than a confirmed discrete catalyst.
What the Numbers Show
The most recently reported quarter, Q1 2026 (announced May 11, 2026), showed a company still working through the aftermath of its migrant-services wind-down. Total Revenue was $75.6 million, down 21.3% from $96.0 million a year earlier, but up roughly 19.3% when migrant-related revenue is excluded from both periods. Medical Transportation revenue rose 2.2% to $51.9 million, while Mobile Health Services revenue, excluding migrant programs, jumped 131% to $23.6 million from $10.2 million, reflecting growth in care-gap-closure and virtual-care work. GAAP gross Margin held roughly flat at 28.1% versus 28.2%, and adjusted gross margin slipped slightly to 31.6% from 32.1%. Profitability moved the wrong way: net loss widened to $16.7 million (a loss of $0.12 per share, versus a consensus estimate near a $0.02 loss and a prior-year loss of $0.09 per share) from $11.1 million, and adjusted EBITDA fell to a loss of $10.2 million from a loss of $3.9 million. Cash, restricted cash and investments declined to about $59.9 million at March 31, 2026, from $68.3 million at year-end 2025. DocGo did not repurchase any stock in Q1 2026, a Reversal from $5.8 million bought back in the same period a year earlier. For full-year 2025, revenue totaled $322.2 million, down from $616.6 million in 2024, with adjusted EBITDA swinging to a loss of $28.6 million from positive $60.3 million, underscoring how large the migrant-contract revenue base had been. Management raised full-year 2026 revenue guidance to $300–$315 million from a prior $290–$310 million, while leaving adjusted EBITDA guidance unchanged at a loss of $5–$10 million, with most of that loss expected in the first half and a return toward profitability targeted for the second half of 2026.
Why Investors Are Paying Attention
DocGo sits at an unusual inflection point. Its legacy migrant-services and pandemic-era emergency-response revenue, which once made it a headline-grabbing, high-margin story, has almost entirely wound down, a process that began with New York City's 2024 decision to end its no-bid contract with the company. What's left is a smaller but arguably more "normal" healthcare-services business: ambulance and non-emergency medical transport, mobile clinical services, and a growing virtual-care arm bolstered by the October 2025 Acquisition of SteadyMD, a nationwide telehealth platform. Investors are watching whether underlying organic growth (management cites core revenue up roughly 19% year-over-year) can offset the base-effect revenue cliff and whether adjusted EBITDA losses narrow as guided. The looming Q2 print, combined with the delayed filing, adds near-term uncertainty to that thesis.
Bull Case
Bulls point to core-business growth: Medical Transportation revenue is expanding, Mobile Health revenue excluding migrant programs more than doubled year-over-year, and management raised full-year revenue guidance for a second consecutive quarter. New initiatives, a CMS ACCESS Model selection, a new SteadyMD virtual-care contract with an online pharmacy for weight-loss prescriptions, expanded mobile phlebotomy through Subsidiary PTI Health in South Florida, and growth in assigned care-gap-closure patients to 1.6 million, suggest Diversification beyond the migrant-contract era. The five Sell-Side analysts covering the stock reportedly carry a consensus "Buy" rating with an average price target near $1.88, implying substantial theoretical upside from current levels, though such targets should be treated cautiously given the stock's Volatility and small float.
Bear Case
The risks are significant. DocGo trades below Nasdaq's $1 minimum-bid-price requirement and only secured a 180-day compliance extension (to January 25, 2027) in July 2026; shareholders approved a reverse split of between 1-for-5 and 1-for-10 at the June 2026 annual meeting, which management could execute if the price doesn't recover organically. Adjusted EBITDA losses widened sharply in Q1 2026, cash declined roughly $8 million sequentially, and Buybacks paused entirely. The delayed 10-Q filing, while framed as routine, adds a layer of uncertainty heading into results. The company also continues to draw law-firm solicitations questioning insider conduct and governance, shareholders separately rejected a proposed charter amendment expanding officer legal protections at the June meeting, though no findings of wrongdoing have been independently verified.
What Could Move the Stock Next?
The clearest near-term catalyst is Monday's Q2 2026 report and conference call, which will show whether adjusted EBITDA losses are narrowing as guided and whether cash burn stabilized. Beyond that, any board decision on executing the authorized reverse split, further updates on Nasdaq compliance, additional SteadyMD or CMS-program contract wins, and progress toward the promised second-half-2026 return to profitability are all plausible swing factors.
A Modest Bounce Ahead of a Bigger Test
DocGo remains a company in transition, shedding a large but temporary migrant-services revenue base while trying to prove its core mobile-health and transportation businesses, plus a newly acquired telehealth arm, can grow profitably. Recent share strength has been modest and has occurred against a backdrop of Nasdaq compliance risk, a delayed quarterly filing, and widening losses in the most recent reported quarter. Monday's second-quarter results and accompanying commentary should offer the clearest evidence yet on whether management's guided path back toward profitability in the second half of 2026 is on track, and investors will likely weigh that report heavily against the stock's already elevated volatility and sub-$1 price.






Please wait processing your request...